<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795951</url>
  </required_header>
  <id_info>
    <org_study_id>MEKOS 07 29P1/2/3/401</org_study_id>
    <nct_id>NCT00795951</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents</brief_title>
  <official_title>Clinical Evaluation of T.R.U.E. TESTÂ® Panel 1.1, 2.1 and 3.1: in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allerderm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allerderm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open, prospective,single-site, non-randomized study of the efficacy and safety of T.R.U.E.
      TEST Panel 1.1, 2.1 and 3.1 allergens in children and adolescents
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open, prospective,single-site, non-randomized study of the efficacy and safety of T.R.U.E.
      TEST Panel 1.1, 2.1 and 3.1 allergens in children and adolescents. After consent and
      enrollment, the timeline is as follows:A. T.R.U.E. TEST panels 1.1, 2.1 ,3.1 will be applied
      to the skin on the subject's back. All patch test panels will remain at the back until
      removed at the #2 Clinic Visit that occurs 2 days later. B. Skin reactions to all patch test
      panel allergens will be evaluated and scored shortly after panel removal.C. Skin reactions
      will be evaluated and scored again at either 3 or 4 days after #1 Clinic Visit. An additional
      follow-up visit (#3B Clinic Visit) may occur days after day 0 if needed to verify skin
      reactions.D. Skin reactions will be evaluated and scored again at the #4 Clinic Visit, which
      will occur 7 days +/- 2 days after #1 Clinic Visit (day 0). E. A follow up visit will take
      place approximately 3 weeks (21 + 2 days) after #1 Clinic Visit (day 0) to record any late or
      persistent reactions, and any adverse events. Investigators may elect to perform this
      evaluation via telephone if no reactions are present.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Performance: Nickel Sulfate</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Neomycin Sulfate</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Wool Alcohol</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Potassium Dichromate</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Caine Mix</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Fragrance Mix</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Colophony</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Paraben Mix</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Negative Control</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Balsam of Peru</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Ethylenediamine Dihydrochloride</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Cobalt Dichloride</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: P-tert Butylphenol Formadehyde Resin</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Epoxy Resin</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Carba Mix</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Black Rubber Mix</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Cl+Me-Isothiazolinone</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Quaternium-15</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Mercaptobenzothiazole</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: p-Phenylenediamine</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Formaldehyde</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Mercapto Mix</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Thimerosal</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Thiuram Mix</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Diazolidinyl Urea</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Imidazolidinyl Urea</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Budesonide</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Tixocortol-21-pivalate</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions at visit 3 or visit 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Performance: Quinoline Mix</measure>
    <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
    <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Reactions</measure>
    <time_frame>7-10 days after patch application</time_frame>
    <description>Number of subjects who presented with late reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent Reactions</measure>
    <time_frame>appear 2-4 days after patch application and last through 7-14 days after application</time_frame>
    <description>Number of subjects who presented with persistent reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritation</measure>
    <time_frame>Visit 2: 48 hours after patch application</time_frame>
    <description>Number of subjects who presented with irritation at patch removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adhesion</measure>
    <time_frame>Day 2: 48 hours after application</time_frame>
    <description>Number of subjects who presented with poor adhesion at patch removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itching/Burning</measure>
    <time_frame>Day 2: 48 hours after patch application</time_frame>
    <description>Number of subjects who presented with itching/burning at patch removal</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Dermatitis, Contact</condition>
  <arm_group>
    <arm_group_label>TRUE Test panels 1.1, 2,1, 3,1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects were patched with TRUE Test panels 1.1, 2,1 and 3.1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T.R.U.E. Test</intervention_name>
    <description>48 hour application of 28 allergens and negative control</description>
    <arm_group_label>TRUE Test panels 1.1, 2,1, 3,1</arm_group_label>
    <other_name>NA no other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms and history potentially consistent with allergic contact dermatitis based on
             symptoms and clinical history (i.e., subjects are visiting the clinic/physician to
             diagnose, treat or resolve this condition).

          -  Children and adolescents 6 to 18 years of age, and in general good health.

          -  Adolescent females 15 years of age or older (or with menarche) must consent to a urine
             pregnancy test; urine test results must be negative for study inclusion.

          -  Informed consent must be signed and understood by subject. If underage, informed
             consent must be signed and understood by parent or legal guardian, consistent with all
             institutional, local and national regulations.

        Exclusion Criteria:

          -  Topical corticosteroid treatment during the last 7 days on or near the test area.

          -  Systemic treatment with corticosteroids or other immunosuppressive during the last 7
             days.

          -  Subjects currently receiving (or received during the previous 3 weeks) other
             investigational drugs, treatments or devices, or participating in another clinical
             study.

          -  Treatment with ultraviolet (UV) light (including tanning) during the previous 3 weeks.

          -  Acute dermatitis outbreak or dermatitis on or near the test area on the back.

          -  Subjects unable to comply with activity restrictions (e.g., protecting test panels
             from excess moisture due to showering or vigorous activity).

          -  Subjects unable or unwilling to comply with multiple return visits.

          -  Female subjects 15 years of age (or with onset of menarche) and older unable to
             consent to a urine pregnancy test, or those with a positive pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Eichenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <results_first_submitted>February 19, 2013</results_first_submitted>
  <results_first_submitted_qc>December 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2014</results_first_posted>
  <last_update_submitted>December 19, 2013</last_update_submitted>
  <last_update_submitted_qc>December 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allergic</keyword>
  <keyword>contact dermatitis</keyword>
  <keyword>contact allergy</keyword>
  <keyword>Type IV</keyword>
  <keyword>Children</keyword>
  <keyword>TRUE TEST</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Single Site- Rady Children's Hospital Recruiting Period-09 December 2008 (first subject enrolled) 27 October 2009 (last subject exited)</recruitment_details>
      <pre_assignment_details>No significant events or approaches</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic Performance: Nickel Sulfate</title>
          <description>Number of subjects with reactions recorded at visit 3 or 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm Study</title>
          <description>All subjects were patched with TRUE Test panels 1.1, 2.1 and 3.1</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.6" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Nickel Sulfate</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <population>All completed subjects were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance: Nickel Sulfate</title>
            <description>Number of subjects with a positive reaction to nickel sulfate at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Nickel Sulfate</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <population>All completed subjects were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Neomycin Sulfate</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <population>The prevalence of allergic contact dermatitis varies greatly (â¤1%-10%) in consecutive subjects. Therefore, estimates of sample size and study power are based on overall AE rates, which are generally similar across populations and test allergens and for which there is relevant historical data.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Neomycin Sulfate</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <population>The prevalence of allergic contact dermatitis varies greatly (â¤1%-10%) in consecutive subjects. Therefore, estimates of sample size and study power are based on overall AE rates, which are generally similar across populations and test allergens and for which there is relevant historical data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Wool Alcohol</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <population>All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Wool Alcohol</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <population>All enrolled subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Potassium Dichromate</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Potassium Dichromate</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Caine Mix</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Caine Mix</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Fragrance Mix</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Fragrance Mix</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Colophony</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Colophony</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Paraben Mix</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Paraben Mix</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Negative Control</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4.</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Negative Control</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Balsam of Peru</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Balsam of Peru</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Ethylenediamine Dihydrochloride</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Ethylenediamine Dihydrochloride</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Cobalt Dichloride</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Cobalt Dichloride</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: P-tert Butylphenol Formadehyde Resin</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: P-tert Butylphenol Formadehyde Resin</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Epoxy Resin</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Epoxy Resin</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Carba Mix</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Carba Mix</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Black Rubber Mix</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Black Rubber Mix</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Cl+Me-Isothiazolinone</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Cl+Me-Isothiazolinone</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Quaternium-15</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Quaternium-15</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Mercaptobenzothiazole</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Mercaptobenzothiazole</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: p-Phenylenediamine</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: p-Phenylenediamine</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Formaldehyde</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Formaldehyde</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Mercapto Mix</title>
        <description>Number of subjects with positive reactions at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Mercapto Mix</title>
          <description>Number of subjects with positive reactions at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Thimerosal</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Thimerosal</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Thiuram Mix</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Thiuram Mix</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Diazolidinyl Urea</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Diazolidinyl Urea</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Imidazolidinyl Urea</title>
        <description>Number of subjects with positive reactions at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Imidazolidinyl Urea</title>
          <description>Number of subjects with positive reactions at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Budesonide</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Budesonide</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Tixocortol-21-pivalate</title>
        <description>Number of subjects with positive reactions at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Tixocortol-21-pivalate</title>
          <description>Number of subjects with positive reactions at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Quinoline Mix</title>
        <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
        <time_frame>Visit 3: 72 hours after patch application, Visit 4: 1 week after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Performance</title>
            <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Quinoline Mix</title>
          <description>Number of subjects with positive reactions recorded at visit 3 or visit 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Reactions</title>
        <description>Number of subjects who presented with late reactions</description>
        <time_frame>7-10 days after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Late Reactions</title>
            <description>Number of subjects who presented with late reactions</description>
          </group>
        </group_list>
        <measure>
          <title>Late Reactions</title>
          <description>Number of subjects who presented with late reactions</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistent Reactions</title>
        <description>Number of subjects who presented with persistent reactions</description>
        <time_frame>appear 2-4 days after patch application and last through 7-14 days after application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Persistent Reactions</title>
            <description>Number of subjects who presented with persistent reactions</description>
          </group>
        </group_list>
        <measure>
          <title>Persistent Reactions</title>
          <description>Number of subjects who presented with persistent reactions</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Irritation</title>
        <description>Number of subjects who presented with irritation at patch removal</description>
        <time_frame>Visit 2: 48 hours after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irritation</title>
            <description>Number of subjects who presented with irritation at patch removal</description>
          </group>
        </group_list>
        <measure>
          <title>Irritation</title>
          <description>Number of subjects who presented with irritation at patch removal</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adhesion</title>
        <description>Number of subjects who presented with poor adhesion at patch removal</description>
        <time_frame>Day 2: 48 hours after application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adhesion</title>
            <description>Number of subjects who presented with poor adhesion at patch removal</description>
          </group>
        </group_list>
        <measure>
          <title>Adhesion</title>
          <description>Number of subjects who presented with poor adhesion at patch removal</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Itching/Burning</title>
        <description>Number of subjects who presented with itching/burning at patch removal</description>
        <time_frame>Day 2: 48 hours after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Itching</title>
            <description>Number of subjects who presented with itching at patch removal</description>
          </group>
        </group_list>
        <measure>
          <title>Itching/Burning</title>
          <description>Number of subjects who presented with itching/burning at patch removal</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Adverse Event-Reporting Period for each study subject began at application of the patch test and ended with the Day 21 visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Safety</title>
          <description>Adverse Events</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Not specified</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of rash</sub_title>
                <counts group_id="E1" events="34" subjects_affected="26" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Flare-up of rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Boil on forehead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Reaction around panel 2.1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Edema, vesiculation pain on hands</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Worsening of underlying condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Slight worsening of spot on leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lesion on right thumb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Worsening of dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Reaction on place of panel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>SE Jacob, MD and L Eichenfield, MD</name_or_title>
      <organization>Rady Childrenâs Hospital, San Diego, CA</organization>
      <phone>858-576-1700 ext 4825</phone>
      <email>leichenfield@rchsd.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

